Healthcare
Live Price
Offline$0.50
-2.15% today
1Y Change
-80.54%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vivos Therapeutics, Inc. (VVOS) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.50 and down 80.5% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +16.0%, EPS growth of +7.2%, a dividend yield of 0.0%. What stands out right now is revenue +16.0%, EPS +7.2%, free cash flow -32.8% with operating margin -114.1% and ROIC -123.2%. Valuation is more restrained than many high-expectation growth names at price/sales 0.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VVOS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VVOS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VVOS Max Drawdown
-91.77%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VVOS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$13.1M
-22.6% YoY
FY Net Income
-$12.1M
+40.6% YoY
Free Cash Flow
-$5.8M
+68.0% YoY
Revenue Growth
+16.0%
EPS Growth
+7.2%
Gross Margin
60.4%
Net Margin
-121.7%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 15M | 14M | 16M | 17M | 13M |
| Gross Profit | 9M | 8M | 10M | 13M | 10M |
| Operating Income | -11M | -17M | -25M | -19M | -9M |
| EBITDA | -11M | -17M | -24M | -20M | -11M |
| Net Income | -11M | -14M | -24M | -20M | -12M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6M | 2M | 4M | 24M | 18M |
| Total Assets | 15M | 11M | 14M | 34M | 25M |
| Total Liabilities | 7M | 10M | 9M | 8M | 8M |
| Shareholder Equity | 8M | 411K | 5M | 26M | 17M |
| Total Debt | 2M | 2M | 2M | 2M | 1M |
| Net Debt | -5M | 352K | -1M | -22M | -17M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
6M
+63.9% YoY
Capital Expenditures
120K
+95.0% YoY
Free Cash Flow
6M
+68.0% YoY
Key ratios
Gross Margin
60.4%
Operating Margin
-114.1%
Net Margin
-121.7%
ROE
-846.5%
Debt / Equity
-9.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.